12.25p-0.38 (-2.97%)09 Dec 2025, 17:36
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Skinbiotherapeutics PLC Fundamentals

Company NameSkinbiotherapeutics PLCLast Updated2025-12-09
IndustryBiotechnologySectorHealthcare
Shares in Issue258.779 mMarket Cap£31.70 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£-0.00EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0819Debt Equity Ratio0.0936
Asset Equity Ratio1.2874Cash Equity Ratio0.5074
Quick Ratio4.2136Current Ratio4.84
Price To Book Value3.4686ROCE0

Skinbiotherapeutics PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Skinbiotherapeutics PLC Company Financials

Assets2025202420232022
Tangible Assets£728,348.00£116,369.00£173,160.00£126,903.00
Intangible Assets£4.29 m£3.43 m£700,331.00£625,504.00
Investments0000
Total Fixed Assets£5.02 m£3.54 m£873,491.00£752,407.00
Stocks£800,154.00£472,419.00£33,497.00£122,571.00
Debtors£1.41 m£341,154.00£13,509.00£12,901.00
Cash & Equivalents£4.78 m£800,904.00£1.31 m£1.80 m
Other Assets0000
Total Assets£12.13 m£5.22 m£2.59 m£3.08 m
Liabilities2025202420232022
Creditors within 1 year£1.47 m£1.80 m£529,741.00£508,959.00
Creditors after 1 year£1.24 m£440,485.00£69,601.00£100,647.00
Other Liabilities0000
Total Liabilities£2.71 m£2.25 m£599,342.00£609,606.00
Net assets£9.42 m£2.97 m£1.99 m£2.48 m
Equity2025202420232022
Called up share capital£2.59 m£2.02 m£1.73 m£1.57 m
Share Premium£21.09 m£14.51 m£10.95 m£8.76 m
Profit / Loss-£715,116.00-£2.95 m-£3.01 m-£2.99 m
Other Equity£9.42 m£2.97 m£1.99 m£2.48 m
Preference & Minorities0000
Total Capital Employed£9.42 m£2.97 m£1.99 m£2.48 m
Ratios2025202420232022
Debt Ratio£0.09£0.01£0.03£0.04
Debt-to-Equity£0.09£0.01£0.03£0.04
Assets / Equity1.28741.28741.28741.2874
Cash / Equity0.50740.50740.50740.5074
EPS-£0.01-£0.02-£0.02-£0.02
Cash Flow2025202420232022
Cash from operating activities-£1.24 m-£2.73 m-£2.65 m-£2.67 m
Cashflow before financing£5.60 m£1.79 m-£327,812.00-£2.71 m
Increase in Cash£3.98 m-£510,930.00-£493,089.00-£2.80 m
Income2025202420232022
Turnover£4.64 m£1.21 m£132,057.00£74,761.00
Cost of sales£1.78 m£525,631.00£46,867.00£29,424.00
Gross Profit£2.86 m£683,038.00£85,190.00£45,337.00
Operating Profit-£1.12 m-£2.91 m-£3.00 m-£2.98 m
Pre-Tax profit-£715,116.00-£2.95 m-£3.01 m-£2.99 m

Skinbiotherapeutics PLC Company Background

SectorHealthcare
ActivitiesSkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.
Latest Interim Date26 Mar 2025
Latest Fiscal Year End Date5 Dec 2025

Skinbiotherapeutics PLC Directors

AppointedNamePosition
2022-04-29Mr. Douglas John QuinnExecutive Director,Chief Financial Officer and Company Secretary
2025-12-05Mr. Martin Braddock Hunt Non-Executive Director,Chairman
2020-12-04Dr. Catherine Anne O'Neill Executive Director,Chief Executive Officer
2025-12-05Dr. Catherine Denise Prescott Non-Executive Director
2025-12-05Mr. Stuart John Ashman Executive Director,Chief Executive Officer
2025-04-24Mr. Manprit Singh RandhawaExecutive Director,Chief Financial Officer and Company Secretary
2025-12-05Ms. Danielle BekkerNon-Executive Director

Skinbiotherapeutics PLC Contact Details

Company NameSkinBioTherapeutics PLC
Address15 Silk House, Park Green, Macclesfield, SK11 7QJ
Telephone+44 1614682760
Websitehttps://www.skinbiotherapeutics.com

Skinbiotherapeutics PLC Advisors

AuditorJeffreys Henry LLP
Phone+44 2073092222
Fax+44 2073092309
Financial PR AdviserInstinctif Partners
Phone+44 2074572020
Fax+44 2078667900
Solicitorturnerparkinson LLP
RegistrarShare Registrars Limited
Phone+44 1252821390
Fax+44 1252719232
Nominated AdviserCairn Financial Advisers LLP
Phone+44 2072130880
StockbrokerTurner Pope Investments (TPI) Ltd
Phone+44 2036214120